Bridge to Life™ Ltd., a global innovator in organ preservation and perfusion technologies, today announced that the U.S. Food and Drug Administration (FDA) has granted De Novo clearance for the ...
In OHCA survivors, longer elevated perfusion pressure duration with MAP >80 mmHg in the first 48 hours after ROSC was ...
A patient who underwent transplant with a liver that was preserved for 3 days outside of the body using warm machine perfusion was healthy and leading a normal life at 1 year, according to researchers ...
Therapeutic hypothermia of donors didn't preserve kidney function as well as machine perfusion of the organ during cold storage, a randomized trial found. Compared with kidneys pumped with a ...
Innovations in bioprocessing have led to rapid advancements in biological therapies, positively impacting the lives of millions. One less-recent innovation, which has seen a refreshed surge in ...
Only a handful of biopharmaceutical companies have heard of a small microbioreactor developer that calls itself Erbi Biosystems. It hasn’t been in stealth mode. Its engineer-founders just weren’t ...
Bridge to Life™ Ltd., a global innovator in organ preservation and perfusion technologies, today announced that the U.S. Food and Drug Administration (FDA) has granted De Novo clearance for the ...
Bridge To Lifetm Secures FDA De Novo Clearance For Vitasmarttm Hypothermic Oxygenated Perfusion (HOPE) System, The First Device Cleared In The U.S. For Hypothermic Oxygenated Perfusion Of Donor Livers ...
An earlier version of this announcement was inadvertently distributed in error. This release supersedes all prior versions and reflects the Company's accurate and complete ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback